Hythiam Announces First Peer-Reviewed Publication of Statistically Significant Results from Randomized, Double-Blind, Placebo-Controlled Study

Scientific Study Focused on Impact of PROMETA® Treatment Program on Alcohol Dependent Subjects

 

LOS ANGELES--(BUSINESS WIRE)--Sep 28, 2009 - Hythiam, Inc. (NASDAQ:HYTM) announced today that the results of a double-blind, placebo-controlled study on the impact of the medical component of the PROMETA® Treatment Program on alcohol dependent subjects was accepted and published in the Journal of Clinical Psychopharmacology, a leading scholarly publication in psychopharmacology that features articles reporting on clinical trials and studies. The article is titled, “Efficacy of a Combination of Flumazenil and Gabapentin in the Treatment of Alcohol Dependence”, Anton RF, Myrick H., et al., Journal of Clinical Psychopharmacology, Volume 29, Number 4, August 2009, pp. 334-342. The study was conducted at the Medical University of South Carolina, and among the researchers' findings were that key results demonstrated a statistically significant difference in use for subjects who exhibited pre-treatment withdrawal symptoms. The results are the first to be published in a peer-reviewed scientific journal from a double-blind, placebo-controlled study conducted to assess the impact of the PROMETA Treatment Program on alcohol dependence.

“We are pleased that results from the double-blind, placebo-controlled studies are beginning to publish in academic journals,” said Hythiam's Senior Vice President of Scientific Affairs, Dr. Gary Ingenito. “Peer-review publication brings additional validation to the PROMETA Treatment Program, and results from the alcohol studies are providing greater clarity for clinicians as to when use of the PROMETA Treatment Program in alcohol dependent patients may be beneficial. We look forward to several publications of results from other completed double-blind studies in peer-reviewed journals, and expect those results to help create a more complete picture regarding the impact of the PROMETA Treatment Program on substance dependence.”

About Hythiam®

Hythiam, Inc. provides through its Catasys subsidiary, specialized behavioral health management services to health plans, employers and unions through a network of licensed and company managed health care providers. The Catasys substance dependence program was designed to address substance dependence as a chronic disease. The program seeks to lower costs and improve member health through the delivery of integrated medical and psychosocial interventions in combination with long term care coaching, including the proprietary PROMETA® Treatment Program for alcoholism and stimulant dependence. The PROMETA Treatment Program, which integrates behavioral, nutritional, and medical components, is also available on a private-pay basis through licensed treatment providers. Hythiam does not practice medicine or manufacture, distribute, or sell any medications and has no relationship with any manufacturers or distributors of medications used in the PROMETA Treatment Program. For further information, please visit www.hythiam.com.

The study, funded by an unrestricted grant provided by Hythiam, was designed, executed, analyzed and reported solely by the article's nine authors.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history and lack of statistically significant formal research studies, the risk that treatment protocols might not be effective, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and substantial regulation in the health care industry; and additional risks factors as discussed in the reports filed by the company with the Securities and Exchange Commission, which are available on its website at http://www.sec.gov.

 

Contact: Investor Relations: Hythiam, Inc. Patricia Aguirre, 310-444-4333 paguirre@hythiam.com

 

Posted: September 2009

View comments

Hide
(web3)